Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:6.4.1.2 (
acetyl-CoA carboxylase
)
2,876
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Insulin induction of
acetyl-CoA carboxylase
(
ACC
) and differentiation of 30A5 preadipocytes into adipocytes requires a brief exposure of the cells to cAMP. Using the techniques of DNase I footprinting, DNA band shift, and analysis of the point and deletion mutations, a region from -113 to -95 has been identified as the site through which cAMP sensitizes the cell for the response to insulin. One sequence-specific DNA-protein complex, b3, is formed in the DNA-mobility shift assay when nuclear extract from 30A5 cells is mixed with the oligonucleotide representing this region. Purified human
AP-2
also generates the complex corresponding to b3 with the same
ACC
PII probe or with the
AP-2
consensus sequence probe from SV40 promoter. Substitution of A for G in the sequence GGGGCTGGG abolishes the formation of b3 sequence-specific complex. Stably transfected 30A5 cells with the same mutations in the plasmid no longer respond to insulin in spite of their exposure to cAMP. These results establish that the 21 base pair region in
ACC
promoter II and the binding of
AP-2
protein to this sequence are required for cAMP action. cAMP-dependent protein kinase phosphorylates
AP-2
both in vitro and in vivo and the phosphorylation of
AP-2
does not affect its binding activity.
...
PMID:The site of cAMP action in the insulin induction of gene expression of acetyl-CoA carboxylase is AP-2. 810 69